Business Context and Reporting Period
Company: CAMP4 Therapeutics Corp (CAMP)
Filing Type: Form 8-K (Current Report)
Date of Report: May 16, 2025
Reporting Period: Single event date (May 16, 2025)
Business Context: The Company is an emerging growth company focused on gene therapy. This filing discloses the presentation of translational data for its SYNGAP1-related disorders program and preclinical/safety data for its Urea Cycle Disorders program at the 28th American Society of Gene and Cell Therapy Annual Meeting.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This Form 8-K is a disclosure of scientific progress and corporate updates rather than a financial statement.
Material Changes
No material financial changes are reported in this document. The material event is the dissemination of clinical and preclinical data regarding two specific therapeutic programs:
- SYNGAP1-Related Disorders: Presentation of data showing increased protein levels in non-human primates.
- Urea Cycle Disorders: Review of preclinical data and detailed single ascending dose safety data.
Guidance, Outlook, and Risks
Management Commentary: The Company issued a press release and updated its corporate slide presentation to highlight the aforementioned scientific milestones.
Risks and Contingencies: The filing explicitly states that the information contained in the press release and slide presentation (Exhibits 99.1 and 99.2) is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not subject to the liabilities of that section, nor is it incorporated by reference into other filings except as expressly set forth.
Guidance: No specific financial guidance or future outlook numbers are provided in this text.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for detailed data on protein increase in non-human primates for the SYNGAP1 program.
- Review Exhibit 99.2 (Slide Presentation) for the full scope of preclinical and safety data for the Urea Cycle Disorders program.
- Verify the Company's cash runway and burn rate in the most recent 10-Q or 10-K, as this 8-K contains no financial data.
- Confirm the timeline for potential clinical trial initiation based on the safety data presented.